Korean Stock Flows

ABL Bio (KRX: 298380)

에이비엘바이오 KOSDAQ Biotech & Pharma 기초 의약물질 제조업
Close (Oct 13, 2026)
₩43,500
-4.61%
Market cap
₩2T ($1.8B)
52-week range
₩41,700 – ₩257,500
P/E (12M fwd) · P/B · Div yield
134.04 · 15.50 · 0%
trailing – · consensus of 3 analysts

Who is buying ABL Bio?

Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net bought ₩34.3bn ($26M) of ABL Bio, the 11th largest foreign net purchase among 1828 KOSDAQ stocks. Institutions net sold ₩53.9bn ($40M) and retail investors net bought ₩24.4bn ($18M) over the same window. Foreigners were net buyers on 12 of the 20 sessions.

Foreign investors hold 14.48% of ABL Bio's listed shares (KRX ownership data as of Oct 13, 2026), up from 13.44% twenty sessions earlier and 12.11% a year ago.

The stock closed at ₩43,500 on Oct 13, 2026: -36.96% over 20 sessions, -78.25% year-to-date, -52.46% over one year. The 52-week range is ₩41,700 – ₩257,500.

At ₩43,500 the stock trades at 134.04× 12-month-forward consensus earnings (3 analysts), 100.77× on FY2027 estimates.

ABL Bio share price, last 60 trading days (KRW)
96,606 77,902 59,198 40,494 Jul 13 Aug 26 Oct 13
Daily foreign investor net purchases, last 60 trading days
+23.2bn +11.6bn -11.6bn -23.2bn Jul 13 Aug 26 Oct 13
View chart data as a table
Date Close Foreign net Institutions Retail
2026-10-13 ₩43,500 ₩-0.1bn +₩1.7bn ₩-1.7bn
2026-10-12 ₩45,600 ₩-1.1bn ₩-0.6bn +₩2.0bn
2026-10-08 ₩48,000 ₩-0.0bn ₩-4.8bn +₩4.6bn
2026-10-07 ₩51,100 ₩-9.5bn +₩0.1bn +₩9.5bn
2026-10-06 ₩52,500 ₩-2.8bn ₩-0.3bn +₩2.9bn
2026-10-02 ₩51,400 ₩-5.1bn ₩-0.0bn +₩5.1bn
2026-10-01 ₩53,600 +₩2.5bn +₩4.2bn ₩-6.5bn
2026-09-30 ₩48,500 ₩-1.3bn ₩-1.3bn +₩1.8bn
2026-09-29 ₩49,300 +₩3.6bn ₩-2.5bn ₩-0.4bn
2026-09-28 ₩50,200 ₩-4.8bn ₩-1.0bn +₩5.7bn
2026-09-23 ₩50,800 +₩12.2bn ₩-6.9bn ₩-4.6bn
2026-09-22 ₩51,100 +₩9.0bn ₩-6.8bn ₩-2.0bn
2026-09-21 ₩53,900 +₩10.2bn ₩-4.6bn ₩-1.3bn
2026-09-18 ₩56,000 +₩1.9bn ₩-6.8bn +₩4.6bn
2026-09-17 ₩58,100 +₩2.7bn ₩-0.3bn ₩-2.9bn
2026-09-16 ₩57,900 +₩12.2bn ₩-14.3bn +₩2.0bn
2026-09-15 ₩59,300 +₩2.3bn ₩-3.5bn +₩1.9bn
2026-09-14 ₩64,900 +₩1.2bn ₩-0.6bn ₩-0.7bn
2026-09-11 ₩66,100 +₩0.6bn ₩-2.8bn +₩2.2bn
2026-09-10 ₩67,800 +₩0.5bn ₩-2.8bn +₩2.1bn
2026-09-09 ₩69,000 +₩1.8bn ₩-3.0bn +₩1.3bn
2026-09-08 ₩68,200 ₩-1.4bn ₩-4.7bn +₩6.0bn
2026-09-07 ₩71,100 ₩-2.8bn +₩0.1bn +₩3.0bn
2026-09-04 ₩71,400 +₩2.3bn +₩3.9bn ₩-5.8bn
2026-09-03 ₩67,600 +₩2.2bn ₩-4.0bn +₩1.6bn
2026-09-02 ₩69,300 +₩4.3bn ₩-3.4bn ₩-1.0bn
2026-09-01 ₩71,000 +₩2.8bn ₩-5.6bn +₩2.7bn
2026-08-31 ₩72,700 ₩-2.7bn ₩-8.1bn +₩11.1bn
2026-08-28 ₩76,900 ₩-13.4bn +₩0.4bn +₩12.9bn
2026-08-27 ₩76,000 +₩5.0bn ₩-2.1bn ₩-2.5bn
2026-08-26 ₩74,600 +₩0.2bn ₩-3.0bn +₩2.8bn
2026-08-25 ₩74,600 +₩6.4bn ₩-7.7bn +₩1.4bn
2026-08-24 ₩75,800 +₩3.5bn ₩-1.1bn ₩-2.3bn
2026-08-21 ₩75,200 ₩-3.3bn ₩-6.1bn +₩9.4bn
2026-08-20 ₩82,500 ₩-6.1bn +₩4.1bn +₩2.1bn
2026-08-19 ₩79,700 +₩0.0bn +₩2.0bn ₩-1.9bn
2026-08-18 ₩79,800 +₩6.5bn ₩-8.0bn +₩1.5bn
2026-08-14 ₩84,100 ₩-0.8bn ₩-9.0bn +₩9.3bn
2026-08-13 ₩86,800 +₩3.4bn ₩-6.1bn +₩2.4bn
2026-08-12 ₩86,800 +₩0.1bn ₩-4.5bn +₩4.0bn
2026-08-11 ₩89,100 ₩-9.7bn ₩-3.4bn +₩13.4bn
2026-08-10 ₩93,600 ₩-23.2bn +₩19.9bn +₩2.5bn
2026-08-07 ₩86,600 ₩-4.6bn +₩3.8bn +₩0.5bn
2026-08-06 ₩83,300 ₩-10.0bn +₩9.2bn +₩1.0bn
2026-08-05 ₩80,200 ₩-4.0bn ₩-0.7bn +₩4.5bn
2026-08-04 ₩80,400 ₩-11.2bn +₩17.1bn ₩-6.1bn
2026-08-03 ₩71,000 ₩-0.2bn +₩1.5bn ₩-1.4bn
2026-07-31 ₩66,800 +₩5.4bn +₩2.7bn ₩-8.2bn
2026-07-30 ₩60,800 +₩6.5bn ₩-1.1bn ₩-5.4bn
2026-07-29 ₩63,300 +₩10.5bn +₩4.9bn ₩-15.4bn
2026-07-28 ₩68,800 +₩0.3bn +₩7.2bn ₩-7.3bn
2026-07-27 ₩72,600 ₩-2.5bn +₩3.9bn ₩-1.4bn
2026-07-24 ₩72,400 +₩0.1bn +₩0.1bn ₩-0.1bn
2026-07-23 ₩74,300 +₩3.4bn +₩3.8bn ₩-7.3bn
2026-07-22 ₩69,400 +₩8.6bn ₩-8.3bn ₩-0.5bn
2026-07-21 ₩69,300 +₩7.6bn ₩-7.3bn ₩-0.0bn
2026-07-20 ₩70,200 +₩5.4bn ₩-3.2bn ₩-2.1bn
2026-07-16 ₩75,600 +₩3.5bn ₩-3.5bn +₩0.5bn
2026-07-15 ₩79,300 +₩7.9bn +₩0.2bn ₩-8.1bn
2026-07-14 ₩74,400 +₩10.4bn ₩-4.3bn ₩-5.8bn
2026-07-13 ₩79,100 +₩1.6bn +₩4.2bn ₩-5.2bn

Investor flows summary

Window Foreign (USD) Institutions Retail
1 day ₩-0.1bn $-0M +₩1.7bn ₩-1.7bn
5 days ₩-13.5bn $-10M ₩-4.0bn +₩17.3bn
20 days +₩34.3bn +$26M ₩-53.9bn +₩24.4bn

Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.

Frequently asked questions

Are foreign investors buying ABL Bio stock?

Over the last 5 sessions foreign investors net sold ₩13.5bn ($10M) of ABL Bio; over 60 sessions they net bought ₩46.2bn ($35M); since Jan 1, 2026 they net sold ₩40.1bn ($30M). Over 20 sessions the stock is the 11th largest foreign net purchase among 1828 KOSDAQ stocks.

How much of ABL Bio do foreign investors own?

Foreign investors own 14.48% of ABL Bio's shares as of Oct 13, 2026, versus 12.11% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.

Who is on the other side — institutions or retail investors?

Over 20 sessions institutions net sold ₩53.9bn ($40M) and retail investors net bought ₩24.4bn ($18M) of ABL Bio. Foreign buying is being met mainly by institutional selling.

Is ABL Bio listed on KOSPI or KOSDAQ?

ABL Bio (에이비엘바이오) trades on KOSDAQ under KRX code 298380 in the Biotech & Pharma group, with a market capitalization of ₩2T ($1.8B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.

Annual financials

Fiscal year Revenue YoY Operating profit Net income
2023 ₩66bn ($49M) – -₩3bn (-$2M) -₩3bn (-$2M)
2024 ₩33bn ($25M) -49.00% -₩59bn (-$45M) -₩56bn (-$42M)
2025 ₩79bn ($60M) +137.60% -₩40bn (-$30M) -₩38bn (-$28M)

Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.

← All foreign investor flows